Subscribe
shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
2 June 2020Americas

PTAB to review Minnesota patent after Gilead petition

Gilead Sciences has persuaded the US Patent Trial and Appeal Board (PTAB) to review an antiviral patent owned by the  University of Minnesota (UM).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Brazil accuses Gilead over 1,421.5% price hike of hep C drug
24 October 2019   The Brazilian Federal Public Defender’s Office has filed a complaint against Gilead for hugely increasing the price of its hepatitis C drug since it gained patent protection.
Americas
No fees award for PTAB proceedings, rules Fed Circuit
5 June 2020   The US Court of Appeals for the Federal Circuit has said it cannot award attorneys’ fees for proceedings before the US Patent Trial and Appeal Board.
Americas
Gilead expands oncology business with Pionyr deal
25 June 2020   Gilead Sciences has begun a potential takeover of Pionyr Immunotherapeutics after it agreed to pay $275 million for a 49.9% equity stake in the cancer research company.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
Brazil accuses Gilead over 1,421.5% price hike of hep C drug
24 October 2019   The Brazilian Federal Public Defender’s Office has filed a complaint against Gilead for hugely increasing the price of its hepatitis C drug since it gained patent protection.
Americas
No fees award for PTAB proceedings, rules Fed Circuit
5 June 2020   The US Court of Appeals for the Federal Circuit has said it cannot award attorneys’ fees for proceedings before the US Patent Trial and Appeal Board.
Americas
Gilead expands oncology business with Pionyr deal
25 June 2020   Gilead Sciences has begun a potential takeover of Pionyr Immunotherapeutics after it agreed to pay $275 million for a 49.9% equity stake in the cancer research company.

More on this story

Big Pharma
Brazil accuses Gilead over 1,421.5% price hike of hep C drug
24 October 2019   The Brazilian Federal Public Defender’s Office has filed a complaint against Gilead for hugely increasing the price of its hepatitis C drug since it gained patent protection.
Americas
No fees award for PTAB proceedings, rules Fed Circuit
5 June 2020   The US Court of Appeals for the Federal Circuit has said it cannot award attorneys’ fees for proceedings before the US Patent Trial and Appeal Board.
Americas
Gilead expands oncology business with Pionyr deal
25 June 2020   Gilead Sciences has begun a potential takeover of Pionyr Immunotherapeutics after it agreed to pay $275 million for a 49.9% equity stake in the cancer research company.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent